Formulations comprising antisense nucleotides to connexins

Details Formulations comprising antisense nucleotides to connexins Formulations comprising antisense nucleotides to connexins

2006-08-29

2006-08-29

McGarry, Sean (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C435S375000, C435S377000, C536S024100, C536S024500, C536S023100

Reexamination Certificate

active

07098190

ABSTRACT:
A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.

REFERENCES:
patent: WO US96/19194 (1998-06-01), None
patent: WO 9824797 (1998-11-01), None
Agrawal S., TIBTECH vol. 14: 376-387, Oct. 1996.
Branch A., TIBS vol. 23:45-50, Feb. 1998.
Jen et al., Stem Cells vol. 18:307-319, 2000.
Qiu et al., Current Biology vol. 13: 1697-1703, Sep. 30, 2004.
Hodgins M., Journal of Investigative Dermatologyvol. 122(5):ix-x, 2004.
R. Ruch et al., Molecular Carcinogenesis, 14:269-274 (1995).
J. Goliger et al., Molecular Biology of the Cell, 6:1491-1501 (1995).
Moore et al., Am J. Physiology, vol. 265, No. 1, pp. C1371-C1388 (1994).
Grazul-Bilska et al., Abstract, Biology Reproduction, vol. 58, No. 1, p. 78 (1998).
European Patent Office, Search Report for Application No. 05016736.0, dated Dec. 19, 2005.
Davis et al., “Modulation of Connexin43 Expression: Effects on Cellular Coupling”, 1995, U.S.
Rozenthal et al., “Stable Transfection with Connexin43 Inhibits Neuronal Differentiation of PC12 Cells”, Oct. 25, 1997, U.S.
Becker et al., “Connexin Alpha1 and Cell Proliferation in the Developing Chick Retina”, Apr. 1999, U.S.
Green et al., “Spatiotemporal Depletion of Connexins Using Antisense Oligonucleotides”, 2001, U.S.
Frantseva et al., “Ischemia-Induced Brain Damage Depends on Specific Gap-Junctional Coupling”, Apr. 2002, U.S.

Affiliated with

Also associated with

Rating

Formulations comprising antisense nucleotides to connexins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Formulations comprising antisense nucleotides to connexins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulations comprising antisense nucleotides to connexins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3674352